Technology

Intra-Cellular Therapies

$32.24
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.95 (-2.86%) Today
$0.00 (0.00%) As of 1:00 AM UTC after-hours

Why Robinhood?

You can buy or sell ITCI and other stocks, options, and ETFs commission-free!

About ITCI

Intra-Cellular Therapies Inc. Common Stock, also called Intra-Cellular Therapies, is a biopharmaceutical company, which focuses on the discovery and clinical development of innovative, small molecule drugs that address underserved medical needs in neuropsychiatric and neurological disorders by targeting intracellular signaling mechanisms within the central nervous system, or CNS. Its lead product candidate, ITI-007, is in clinical development as a first-in-class treatment for schizophrenia. The company also includes pre-clinical programs that are focused on advancing drug candidates for the treatment of cognitive dysfunction, in both schizophrenia and Alzheimer's disease, and for disease modification and the treatment of neurodegenerative disorders, including Alzheimer's disease. The company was founded by Paul Greengard and Sharon Mates on August 29, 2013 and is headquartered in New York, NY. The listed name for ITCI is Intra-Cellular Therapies Inc. Common Stock.

CEO
Sharon Mates
Employees
330
Headquarters
New York, New York
Founded
2013
Market Cap
2.58B
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
737.08K
High Today
$33.37
Low Today
$31.80
Open Price
$33.15
Volume
664.27K
52 Week High
$34.95
52 Week Low
$10.94

Collections

ITCI Earnings

-$1.00
-$0.67
-$0.33
$0.00
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Estimated
— per share
Actual
Expected Mar 1, Pre-Market

You May Also Like

MYF
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure